HSCT

19 registered clinical trials studyying HSCT — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantati NCT07456189	Institute of Hematology & Blood Diseases Hospital, China	N/A
Not Yet Recruiting	Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). NCT07476872	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Not Yet Recruiting	Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis NCT07471503	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed NCT07443488	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT NCT07450313	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Fu NCT07408713	Rigshospitalet, Denmark	—
Not Yet Recruiting	Zuberitamab for EBV Infection Post-Allo-HSCT NCT07261215	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome NCT07316595	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 2
Not Yet Recruiting	Modified Conditioning Regimen for CML-BP NCT07259161	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. NCT07157670	Assistance Publique - Hôpitaux de Paris	—
Not Yet Recruiting	Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Tr NCT07193420	Assistance Publique - Hôpitaux de Paris	Phase 3
Recruiting	Romiplostim N01 for Platelet Recovery After Haploidentical HSCT NCT07321626	First Affiliated Hospital of Zhejiang University	Phase 1
Not Yet Recruiting	Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia NCT06769568	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL NCT06658925	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Recruiting	Comparison of Intralipid With SMOF Lipid Following HSCT NCT06625372	Shahid Beheshti University	N/A
Completed	Patient Reported Outcomes and Patient Education in Cellular Therapy Patients NCT04853277	Dartmouth-Hitchcock Medical Center	N/A
Unknown	Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence NCT04078399	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	N/A
Unknown	Modification of the Human Colon and Oral Microbiome by Allogenic HSCT NCT03942159	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	—
Unknown	Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After H NCT03210090	Maimónides Biomedical Research Institute of Córdoba	—